143 related articles for article (PubMed ID: 11806984)
1. Efficacy and safety of thalidomide in patients with acute myeloid leukemia.
Steins MB; Padró T; Bieker R; Ruiz S; Kropff M; Kienast J; Kessler T; Buechner T; Berdel WE; Mesters RM
Blood; 2002 Feb; 99(3):834-9. PubMed ID: 11806984
[TBL] [Abstract][Full Text] [Related]
2. Thalidomide for the treatment of acute myeloid leukemia.
Steins MB; Bieker R; Padró T; Kessler T; Kienast J; Berdel WE; Mesters RM
Leuk Lymphoma; 2003 Sep; 44(9):1489-93. PubMed ID: 14565649
[TBL] [Abstract][Full Text] [Related]
3. [Angiogenesis in patients with hematologic malignancies].
Mesters RM; Padró T; Steins M; Bieker R; Retzlaff S; Kessler T; Kienast J; Berdel WE
Onkologie; 2001 Sep; 24 Suppl 5():75-80. PubMed ID: 11600818
[TBL] [Abstract][Full Text] [Related]
4. Single agent thalidomide in patients with relapsed or refractory acute myeloid leukaemia.
Thomas DA; Estey E; Giles FJ; Faderl S; Cortes J; Keating M; O'Brien S; Albitar M; Kantarjian H
Br J Haematol; 2003 Nov; 123(3):436-41. PubMed ID: 14617002
[TBL] [Abstract][Full Text] [Related]
5. Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia.
Padró T; Ruiz S; Bieker R; Bürger H; Steins M; Kienast J; Büchner T; Berdel WE; Mesters RM
Blood; 2000 Apr; 95(8):2637-44. PubMed ID: 10753845
[TBL] [Abstract][Full Text] [Related]
6. Phase II evaluation of thalidomide in patients with metastatic breast cancer.
Baidas SM; Winer EP; Fleming GF; Harris L; Pluda JM; Crawford JG; Yamauchi H; Isaacs C; Hanfelt J; Tefft M; Flockhart D; Johnson MD; Hawkins MJ; Lippman ME; Hayes DF
J Clin Oncol; 2000 Jul; 18(14):2710-7. PubMed ID: 10894870
[TBL] [Abstract][Full Text] [Related]
7. Thalidomide therapy for myelofibrosis with myeloid metaplasia.
Thomas DA; Giles FJ; Albitar M; Cortes JE; Verstovsek S; Faderl S; O'Brien SM; Garcia-Manero G; Keating MJ; Pierce S; Zeldis J; Kantarjian HM
Cancer; 2006 May; 106(9):1974-84. PubMed ID: 16583431
[TBL] [Abstract][Full Text] [Related]
8. The treatment of advanced renal cell cancer with high-dose oral thalidomide.
Stebbing J; Benson C; Eisen T; Pyle L; Smalley K; Bridle H; Mak I; Sapunar F; Ahern R; Gore ME
Br J Cancer; 2001 Sep; 85(7):953-8. PubMed ID: 11592764
[TBL] [Abstract][Full Text] [Related]
9. Downregulation of neuropilin-1 in patients with acute myeloid leukemia treated with thalidomide.
Kreuter M; Steins M; Woelke K; Buechner T; Berdel WE; Mesters RM
Eur J Haematol; 2007 Nov; 79(5):392-7. PubMed ID: 17916085
[TBL] [Abstract][Full Text] [Related]
10. Angiogenesis in acute myeloid leukemia and myelodysplastic syndrome.
Albitar M
Acta Haematol; 2001; 106(4):170-6. PubMed ID: 11815714
[TBL] [Abstract][Full Text] [Related]
11. Tumor angiogenesis in the bone marrow of multiple myeloma patients and its alteration by thalidomide treatment.
Du W; Hattori Y; Hashiguchi A; Kondoh K; Hozumi N; Ikeda Y; Sakamoto M; Hata J; Yamada T
Pathol Int; 2004 May; 54(5):285-94. PubMed ID: 15086832
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of thalidomide in patients with metastatic malignant melanoma.
Reiriz AB; Richter MF; Fernandes S; Cancela AI; Costa TD; Di Leone LP; Schwartsmann G
Melanoma Res; 2004 Dec; 14(6):527-31. PubMed ID: 15577325
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas.
Fine HA; Figg WD; Jaeckle K; Wen PY; Kyritsis AP; Loeffler JS; Levin VA; Black PM; Kaplan R; Pluda JM; Yung WK
J Clin Oncol; 2000 Feb; 18(4):708-15. PubMed ID: 10673511
[TBL] [Abstract][Full Text] [Related]
14. Thalidomide therapy in compensated and decompensated myelofibrosis with myeloid metaplasia.
Pozzato G; Zorat F; Nascimben F; Comar C; Kikic F; Festini G
Haematologica; 2001 Jul; 86(7):772-3. PubMed ID: 11454539
[No Abstract] [Full Text] [Related]
15. Antitumor activity of thalidomide in refractory multiple myeloma.
Singhal S; Mehta J; Desikan R; Ayers D; Roberson P; Eddlemon P; Munshi N; Anaissie E; Wilson C; Dhodapkar M; Zeddis J; Barlogie B
N Engl J Med; 1999 Nov; 341(21):1565-71. PubMed ID: 10564685
[TBL] [Abstract][Full Text] [Related]
16. Thalidomide in advanced hepatocellular carcinoma as antiangiogenic treatment approach: a phase I/II trial.
Pinter M; Wichlas M; Schmid K; Plank C; Müller C; Wrba F; Peck-Radosavljevic M
Eur J Gastroenterol Hepatol; 2008 Oct; 20(10):1012-9. PubMed ID: 18787470
[TBL] [Abstract][Full Text] [Related]
17. A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma.
Rajkumar SV; Witzig TE
Cancer Treat Rev; 2000 Oct; 26(5):351-62. PubMed ID: 11006136
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial and pharmacokinetic study of thalidomide in patients with metastatic colorectal cancer.
Dal Lago L; Richter MF; Cancela AI; Fernandes SA; Jung KT; Rodrigues AC; Costa TD; Di Leone LP; Schwartsmann G
Invest New Drugs; 2003 Aug; 21(3):359-66. PubMed ID: 14578685
[TBL] [Abstract][Full Text] [Related]
19. Anti-angiogenic activity of the purine analog 6-thioguanine.
Presta M; Belleri M; Vacca A; Ribatti D
Leukemia; 2002 Aug; 16(8):1490-9. PubMed ID: 12145690
[TBL] [Abstract][Full Text] [Related]
20. Results of a phase II study of thalidomide and azacitidine in patients with clinically advanced myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and low blast count acute myeloid leukemia (AML).
Kenealy M; Patton N; Filshie R; Nicol A; Ho SJ; Hertzberg M; Mills T; Prosser I; Link E; Cowan L; Zannino D; Seymour JF
Leuk Lymphoma; 2017 Feb; 58(2):298-307. PubMed ID: 27268068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]